“We are very encouraged to observe a 67% overall survival rate at 3-year follow-up in this Phase I study, which treats the same patient population as our UV1 Phase II study, INITIUM. These data further strengthen the previously reported results from the study, including good safety for UV1 and remarkable 33% complete response rate in patients with metastatic malignant melanoma where surgery is not an option. The data continue to show that UV1 in combination with pembrolizumab has promising signs of efficacy,” said Jens Bjørheim, Chief Medical Officer at Ultimovacs. “We are looking forward to receiving more data from the UV1 clinical trials, to advance UV1 further to the benefit of cancer patients.”
